India · Delayed Price · Currency is INR Anupam Rasayan India Earnings Call Transcripts
Fiscal Year 2027
-
Q1 FY27 total income rose 36% YoY and EBITDA grew 35%, while PAT increased 6% amid higher depreciation. Growth plans center on new product ramps, Jayhawk and the pending Bliss acquisition; full-year EBITDA margin guidance is 22%-24% consolidated.
Fiscal Year 2026
-
FY26 revenue rose 65% to INR 2,384 crore, with INR 334 crore of operating cash flow and greater pharma and materials exposure. Growth plans center on acquisitions, pipeline commercialization and capacity utilization, while Bliss completion and integration remain key execution factors.
-
9M FY26 revenue rose 84% YoY, with growth from pharma, agro recovery, and performance materials. Jayhawk would add U.S. manufacturing and high-value market access; working-capital days are targeted below 200 in FY27.
-
Q2 revenue rose 149% YoY to INR 731 crore, while H1 revenue grew 122% to INR 1,217 crore. FY26 growth guidance is 50%+, with margin recovery expected as older inventory clears and agro, pharma, and polymer demand improves.
-
Q1 FY26 revenue from operations rose 91% YoY and EBITDA rose 118%, while management projected FY26 revenue growth above 30%. New agreements lifted the order book to INR 14,646 crore; inventory reduction and debt repayment are expected to improve the balance sheet.
Fiscal Year 2025
-
The acquisition adds Jayhawk’s U.S. manufacturing, advanced chemistries and customer base, with ~$150 million in consideration and expected day-one EPS accretion. Integration will initially preserve U.S. operations, then pursue selective expansion and a dual-site supply model.
-
Q4 revenue and profit rebounded, while FY25 revenue softened amid earlier macro and agro demand weakness. Management expects 25%-30%+ growth from FY26, led by volume recovery, LOI ramp-ups and new capacity; working capital and commercialization timing remain key execution factors.
-
Q3 FY25 revenue rose 32% YoY and PAT more than doubled, while 9M revenue remained lower amid agrochemical weakness and customer exits. FY26 growth is targeted at 30%-35% on a standalone basis, supported by pharma, polymer and contract commercialization.
-
Q2 revenue fell 25% YoY amid subdued agro demand, while pharma and polymer growth and an improving H2 outlook offer support. FY25 revenue is expected to match FY24, with 25%–27% medium-term EBITDA margin guidance.
-
Q1 FY25 revenue and profit declined amid agrochem order deferrals, while pharma and polymer expanded the revenue mix. Management expects deferred demand and contract ramp-ups to support H2 recovery and anticipates increasing contributions from fluorinated products.
Fiscal Year 2024
-
FY24 revenue and profit declined amid agrochemical weakness and customer destocking, while EBITDA margins held firm. FY25 growth is expected as pharma and polymer expand, though H1 demand and elevated working capital remain challenges.